<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02848508</url>
  </required_header>
  <id_info>
    <org_study_id>PI2016_843_0009</org_study_id>
    <nct_id>NCT02848508</nct_id>
  </id_info>
  <brief_title>Metformin in Moderate and Severe Renal Failure (CKD 3-4): A Follow-up Study</brief_title>
  <acronym>METsuiviIRC</acronym>
  <official_title>Metformin in Moderate and Severe Renal Failure (CKD 3-4): A Follow-up Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <brief_summary>
    <textblock>
      To validate on the mid-term in moderate and severe renal failure (CKD 3-4) a nomogram to
      adapt a fixed metformin daily posology according to renal function on the basis of the first
      short-term study made by the investigators.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A first open-label pilot study at different stages of CKD (1-5) (concerning whether or not
      metformin use is safe provided a dose adjustment is used) has evaluated (i) metformin levels
      in plasma and in erythrocytes according to an increasing metformin dosage and CKD severity
      (1-5) and (ii) the prevalence of lactate levels â‰¥2.5 mmol/L in CKD 3-5. All patients
      underwent 3 one-week- blocks of metformin treatment at an increasing dosage, each of which
      followed by a one week-wash- out period: 500 mg/day in the evening (E) in phase 1; 1,000
      mg/day (500 mg morning (M) and E) in phase 2; 2,000 mg/day (1,000 mg M and E) in phase 3.

      Steady-state trough blood levels were assayed 12 hours after the last dose of metformin. In
      this study a progressive dose-related increase of the trough metformin levels were observed
      and in particular in severe CKD stages. No case of severe hyperlactatemia was reported in
      this study. In continue, the investigators thought to conduct a new study to evaluate safety
      of metformin in mid-term period of time. For this purpose, metformin will be given at a fixed
      dose during 4 months: 1) 1,500 mg/day (500 mg M and 1,000 mg E) in stage 3a; 2) 1,000 mg/day
      (500 mg M and E) in stage 3b; and 3) 500 mg/day (M) in stage 4. Metformin levels in plasma
      and in erythrocytes, venous lactate, and HbA1c levels will be measured at 1, 2, 3 and 4
      months for assessment of safety.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Monitoring of blood metformin plasma levels with a fixed dose of metformin</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Monitoring of blood metformin erythrocytes levels with a fixed dose of metformin</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Renal Insufficiency, Chronic</condition>
  <arm_group>
    <arm_group_label>moderate impairment, CKD stage 3a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(12 subjects): GFR 59-45 (moderate impairment, CKD stage 3a) Metformin : 1500mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>moderate impairment, CKD stage 3a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(12subjects): GFR 44-30 (moderate impairment, CKD stage 3b) Metformin : 1000mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>severe impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(12 subjects): GFR 29-15 (severe impairment, CKD stage 4) Metformin : 500mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>moderate impairment, CKD stage 3a</arm_group_label>
    <arm_group_label>moderate impairment, CKD stage 3a)</arm_group_label>
    <arm_group_label>severe impairment</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes patients with stable CKD stages 3A, 3B and 4 aged between 18 and 80
             years requiring metformin (and any other antidiabetic treatment)

        Exclusion Criteria:

          -  Hyperlactatemia (&gt; 2.5 mmol/L)

          -  No creatinine levels available since 3 months

          -  Severe hepatic insufficiency

          -  No liver function parameters available

          -  Need of investigation with iodized contrast media

          -  Hypersensitivity to metformin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Daniel LALAU, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Daniel LALAU, MD, PhD</last_name>
    <phone>+33 3 22 45 58 95</phone>
    <email>lalau.jean-daniel@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Daniel LALAU, MD, PhD</last_name>
      <phone>+33 3 22 45 58 95</phone>
      <email>lalau.jean-daniel@chu-amiens.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2016</study_first_submitted>
  <study_first_submitted_qc>July 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2016</study_first_posted>
  <last_update_submitted>July 27, 2016</last_update_submitted>
  <last_update_submitted_qc>July 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metformin</keyword>
  <keyword>moderate renal failure</keyword>
  <keyword>severe renal failure</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>hyperlactatemia</keyword>
  <keyword>lactic acidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

